Gastrointestinal hormone measurably improved symptoms of non-alcoholic fatty liver disease
Through a randomized, double-blind, placebo-controlled phase II clinical trial, researchers at University of California San Diego School of Medicine report that small doses of NGM282, a non-tumorigenic variant of an endocrine ...
Mar 8, 2018
0
47